Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
CalciMedica, Inc. NASDAQ:CALC) Chief Business Officer Eric W. Roberts reported purchasing 2,000 shares of common stock on July 18, 2025. The shares were bought at a price of $2.88, totaling $5,760. The purchase comes as the stock has shown strong momentum, with InvestingPro data showing a 26% return over the past week, though technical indicators suggest the stock may be overbought.
Following the transaction, Roberts directly holds 164,706 shares and indirectly holds 46,323 shares through FMTC Custodian - Roth IRA FBO Eric W. Roberts, 49,894 shares through Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares through IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares through Valence Investments SPV IV, LLC, 66,228 shares through Valence Investments SPV V, LLC and 316,109 shares through Valence Investments SPV VI, LLC.
The transaction was signed off by John Dunn, Esq., Attorney-in-Fact, on July 18, 2025.
In other recent news, CalciMedica Inc. has announced the design of its Phase 2 KOURAGE trial for the treatment of acute kidney injury (AKI) with respiratory failure. The trial, which will include approximately 150 patients, aims to evaluate the efficacy of Auxora, a calcium release-activated calcium (CRAC) channel inhibitor, in improving outcomes for patients with severe AKI. The company expects to have data from this trial by the end of 2025. In another development, CalciMedica has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following a merger with Moss Adams LLP. This change was approved by the company’s Board of Directors’ Audit Committee, and there were no disagreements with Moss Adams on accounting practices prior to the merger. The audit report from Moss Adams for the year ending December 31, 2024, was issued without any adverse opinions. CalciMedica has confirmed that it did not consult with Baker Tilly on accounting matters before the merger. This information is based on press release statements and SEC filings from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.